Used as a key intermediate in the synthesis of suvorexant, a dual orexin receptor antagonist prescribed for the treatment of insomnia. It plays a critical role in modulating wakefulness by blocking orexin signaling in the brain. Due to its specific structural features, it enables high selectivity and binding affinity to orexin receptors, contributing to the efficacy and safety profile of the final pharmaceutical product. The compound is primarily utilized in controlled environments during drug manufacturing and formulation processes.